Eflucimibe, formerly known as F-12511; L-0081, is an ACAT inhibitor potentially for the treatment of atherosclerosis and hyperlipidemia. F 12511 regulates endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet. F 12511 inhibited ACAT activity with IC(50) values of 3, 7, and 71 nM, respectively. In vivo, orally administered F 12511 displayed high potency and efficacy as an antihypercholesterolemic compound in different cholesterol-fed animals (rat, guinea-pig, rabbit). References: Zhang XF, O'Shea H, Kehoe S, Boyd D. Time-dependent evaluation of mechanical properties and in vitro cytocompatibility of experimental composite-based nerve guidance conduits. J Mech Behav Biomed Mater. 2011 Oct;4(7):1266-74. doi: 10.1016/j.jmbbm.2011.04.013. PubMed PMID: 21783135.

纯度：≥98%

CAS：202340-45-2